Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristine B Patterson

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 16, 2013
Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosingBenjamin N Greener, Kristine B Patterson, Heather M A Prince, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 22, 2016
Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial DesignMackenzie L Cottrell, Heather M A Prince, Andrew Allmon, et al.
Antiviral Therapy|January 6, 2016
Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapyJulie B Dumond, Owen Francis, Mackenzie Cottrell, et al.
The Journal of Infectious Diseases|February 27, 2016
A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without EmtricitabineMackenzie L Cottrell, Kuo H Yang, Heather M A Prince, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2015
Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257Ighovwerha Ofotokun, Lumine H Na, Raphael J Landovitz, et al.
AIDS Research and Human Retroviruses|September 29, 2015
Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)Craig W Hendrix, Adriana Andrade, Namandjé N Bumpus, et al.
Annals of Internal Medicine|October 7, 2014
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trialJeffrey L Lennox, Raphael J Landovitz, Heather J Ribaudo, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 16, 2013
Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosingBenjamin N Greener, Kristine B Patterson, Heather M A Prince, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 22, 2016
Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial DesignMackenzie L Cottrell, Heather M A Prince, Andrew Allmon, et al.
Antiviral Therapy|January 6, 2016
Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapyJulie B Dumond, Owen Francis, Mackenzie Cottrell, et al.
The Journal of Infectious Diseases|February 27, 2016
A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without EmtricitabineMackenzie L Cottrell, Kuo H Yang, Heather M A Prince, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2015
Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257Ighovwerha Ofotokun, Lumine H Na, Raphael J Landovitz, et al.
AIDS Research and Human Retroviruses|September 29, 2015
Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)Craig W Hendrix, Adriana Andrade, Namandjé N Bumpus, et al.
Annals of Internal Medicine|October 7, 2014
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trialJeffrey L Lennox, Raphael J Landovitz, Heather J Ribaudo, et al.
Pageof 4